Theranos vs WeWork — Two Frauds, Two Different Kinds of Delusion

History will likely remember them together: the two great frauds — or near-frauds — of Silicon Valley's peak confidence era, the years between 2015 and 2019 when venture capital was so abundant and founder mythology so powerful that scrutiny felt almost rude. But Elizabeth Holmes and Adam Neumann represent fundamentally different failure modes, and conflating them obscures the more important lessons both offer.

Theranos was a crime. Holmes founded the company at 19, dropped out of Stanford, and spent a decade raising nearly $700 million from investors including Rupert Murdoch, Betsy DeVos, and some of the most sophisticated family offices in America — on the claim that Theranos could run hundreds of diagnostic blood tests from a single finger prick, faster and cheaper than any existing lab. The problem was that this was not true. The Edison device, Theranos's proprietary analyzer, could reliably run only a small number of tests. For the rest, Theranos diluted patient samples and ran them on commercially available Siemens analyzers — while billing them and reporting results as if they came from the Edison machine. Patients received false results. Medical decisions were made based on fabricated data. Holmes knew. The company was dissolved, and Holmes was convicted in 2022 of investor fraud.

WeWork was something different: a genuinely useful business with real revenues — $1.8 billion in 2018 — deluded by its founder and its primary investor (SoftBank's Vision Fund) into believing it was worth $47 billion. Adam Neumann was charismatic, visionary, and spectacularly bad at thinking about unit economics. WeWork leased office space on long-term contracts and subleased it short-term to startups and freelancers — a business with genuine demand but structural leverage risk, thin margins, and no competitive moat. Neumann called it a "physical social network" and a technology company. SoftBank's Masayoshi Son, who once spent a 12-minute meeting deciding to invest $4.4 billion on the basis of "animal smell," agreed.

The IPO prospectus in 2019 was the moment reality intervened. Public market investors, less enchanted than private ones, looked at a company losing $219,000 per hour, with a CEO who had sold the company's own trademark back to it for $6 million, whose wife had co-signing rights on his replacement if he were incapacitated, and who had taken enormous personal loans against his shares. The IPO was withdrawn within weeks. Neumann walked away with approximately $700 million in various payments negotiated as part of his departure. WeWork limped on, eventually went public via SPAC in 2021 at a fraction of the earlier valuation, and filed for bankruptcy in 2023. The community space business that Theranos and WeWork both claimed to be changing — healthcare and work respectively — survived both of them. The companies did not.